This attention to innovation began to pay off in the 1980s ... downs Like most pharma companies of its size, Pfizer has faced its fair share of controversy as one of the most well-known drugmakers ...

Risperdal is well-known due to the controversy ... to pay $716 million in September and an additional $1.73 billion the following February. William C. Weldon became the Chairman and CEO of J ...

Institutional Shareholder Services has recommended Pfizer investors reject a proposal on executive compensation at its upcoming annual meeting, citing concerns about certain changes made to long-term ...

(Reuters) -Institutional Shareholder Services has recommended Pfizer investors ... and undermine a "pay-for-performance philosophy", ISS said. Annual incentives for executives are tied to ...

Donald Trump takes biopharma on a tariff-themed rollercoaster ride; J&J kicks off the Q1 earnings season; experts express concern about the FDA’s future; Pfizer’s obesity setback could be Viking’s ...

Institutional Shareholder Services has recommended Pfizer investors ... and undermine a “pay-for-performance philosophy,” ISS said. Annual incentives for executives are tied to achieving ...

A third person is expected to be interviewed soon, though Pfizer executives have not yet been questioned. Pfizer maintains that its vaccine development was driven purely by science and regulatory ...

Shareholders are being urged to vote against the pay packages of senior executives at U.S. investment bank Goldman Sachs (GS).Don't Miss Our ...

The proxy adviser said on Wednesday that the changes added about $1 million in additional value for CEO. The modification "significantly undermines the at-risk nature of the awards and a ...